Medtronic to webcast renal denervation investor & analyst briefing on November 7
Medtronic plc (NYSE:MDT) announced a live webcast on November 7, 2022, at 5 p.m. CST, to discuss updates on its Coronary and Renal Denervation business during AHA 2022. The webcast will feature management remarks and present the 6-month results from the SPYRAL HTN-ON MED Randomized Trial. The ON MED data will be presented earlier that day, starting at 3:38 p.m. CST. A press release detailing the ON MED results will also be issued on the same date. A replay of the webcast will be available within 24 hours on Medtronic's investor relations page.
- None.
- None.
DUBLIN, Oct. 14, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the company will host a webcast to provide an update on its Medtronic Coronary and Renal Denervation business during the American Heart Association annual scientific sessions (AHA 2022) on Monday, November 7, 2022, at 5 p.m. CST. The webcast will feature remarks from Medtronic Coronary and Renal Denervation management, including comments on the 6-month results from the SPYRAL HTN-ON MED Randomized Trial (ON MED). These data will be presented as part of a late-breaking science session at AHA 2022 on November 7, with the ON MED data presentation scheduled to begin at approximately 3:38 p.m. CST. The company intends to issue a press release discussing the ON MED results on November 7 at the start of the ON MED late-breaking science session presentation.
The live audio webcast of the investor and analyst briefing can be accessed by clicking on the Investor Events link at http://investorrelations.medtronic.com on November 7, 2022. Within 24 hours of the webcast, a replay will be available on the same webpage. The investor and analyst briefing is not part of the official AHA 2022 program.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts: | |
Erika Winkels | Ryan Weispfenning |
Public Relations | Investor Relations |
+1-763-526-8478 | +1-763-505-4626 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-to-webcast-renal-denervation-investor--analyst-briefing-on-november-7-301649793.html
SOURCE Medtronic plc
FAQ
When will Medtronic host its Coronary and Renal Denervation webcast?
What are the key topics for the Medtronic webcast on November 7, 2022?
What time will the ON MED data be presented during AHA 2022?
Where can I access the Medtronic investor webcast?
Will there be a press release regarding the ON MED results?
